Information Provided By: 
Fly News Breaks for February 23, 2017
TXMD
Feb 23, 2017 | 13:55 EDT
Following quarterly results, Stifel analyst Annabel Samimy notes that TherapeuticsMD's shares remain pressured despite continual evidence of positive late-stage clinical data, favorable regulatory environment, rational commercial strategy, and identifiable market opportunity. The analyst remains positive on the name as TherapeuticsMD transforms itself into a fully commercial-stage company. Samimy reiterated a Buy rating on the stock and raised her price target on the shares to $20 from $17.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
